Abstract
Background: MicroRNAs (miRNAs) have been identified as important participants in the development of atherosclerosis (AS). The present study explored the role of miR-128-3p in the dysfunction of vascular smooth muscle cells (VSMCs) and the underlying mechanism.

Methods: Human VSMCs and ApoE knockout (ApoE−/−) C57BL/6J mice were used to establish AS cell and animal models, respectively. Expression levels of miR-128-3p, forkhead box O4 (FOXO4) and matrix metallopeptidase 9 (MMP9) were detected using qRT-PCR and Western blot, respectively. CCK-8, BrdU, and Transwell assays as well as flow cytometry analysis were performed to detect the proliferation, migration and apoptosis of VSMCs. Levels of inflammatory cytokines and lipids in human VSMCs, mice serum and mice VSMCs were also determined. The binding site between miR-128-3p and 3′UTR of FOXO4 was confirmed using luciferase reporter gene assay.

Results: MiR-128-3p was found to be decreased in AS patient serum, ox-LDL-treated VSMCs, AS mice serum and VSMCs of AS mice. Transfection of miR-128-3p mimics suppressed the proliferation and migration of VSMCs, accompanied by the promoted apoptosis and the decreased levels of inflammatory cytokines. Further experiments confirmed the interaction between miR-128-3p and FOXO4. Augmentation of FOXO4 or MMP9 reversed the effects of miR-128-3p. Besides, miR-128-3p inhibited triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) but increased high-density lipoprotein cholesterol (HDL-C) in the serum of AS mice.

Conclusion: MiR-128-3p repressed the proliferation and migration of VSMCs through inhibiting the expressions of FOXO4 and MMP9.

Keywords: MiR-128-3p, FOXO4, MMP9, Vascular smooth muscle cell, Atherosclerosis

Introduction
Atherosclerosis (AS) is an inflammatory vascular disease, which contributes to the pathogenesis of a variety of cardiovascular diseases (CVD) (Gholipour et al. 2018). CVD remains the cause of about one third of mortality in the world (Moss and Ramji 2016). However, presently, the early diagnosis of AS is still difficult (Bejarano et al. 2018), and the treatment aims at repressing the levels of blood lipids, which has no direct effect on the formation of AS plaques (Orekhov and Ivanova 2016). The development of AS is elicited by inflammation and the dysfunction of vascular smooth muscle cells (VSMCs) (Paone et al. 2019). After vascular injury, VSMCs undergo phenotype-switching, followed by the release of inflammatory factors and the abnormal proliferation and migration, contributing to the formation of AS plaques; receptors such as LOX-1 on the cell membrane of VSMCs, activated by inflammatory factors such as TNF-α, will further promote the inflammatory responses through signaling pathways such as NF-κB, increase the
expressions of cell adhesion factors, and thus further accelerate AS development (Byon et al. 2015; Lim and Park 2014; Jang et al. 2017). Therefore, modulating the inflammatory responses and the phenotypes of VSMCs is a potential strategy to repress the development of AS.

MicroRNAs (miRNAs) are non-coding RNAs with a length of 19–25nt. Accumulating researches suggest that miRNAs may be potential diagnostic and therapeutic targets for AS (Laffont and Rayner 2017). For example, miR-181b is found to be significantly increased in AS plaques, and in AS animal models established using ApoE and LDLR knockout mice, miR-181b enhances the stability of AS plaques by inhibiting target genes such as TIMP-3 and Elastin (Gregoli et al. 2017). MiR-128-3p is a tumor suppressor in a variety of tumors. For instance, in breast cancer, miR-128-3p triggers cell cycle arrest in cancer cells by repressing LIMK1 (Zhao et al. 2019a). In recent years, miR-128-3p has also been found to exert a protective role in CVD. It has been found that oxidized low density lipoprotein (OX-LDL)-treated RAW264.7 cells present remarkable reduction of miR-128-3p expression in a time and dose-dependent manner; while after the transfection of miR-128-3p mimics, it was found that both apoptosis and inflammatory responses were suppressed in RAW264.7 cells (Chen et al. 2018). This suggests that miR-128-3p can repress OX-LDL-induced inflammation and oxidative stress in macrophages, and inhibit the progression of AS.

Forkhead box protein O4 (FOXO4) is a member of the forkhead box O protein family. In cancer biology, FOXO4 is often considered to exert tumor-suppressive effects (Wang et al. 2016). An increasing number of studies have found that FOXO4 also has a regulatory role in AS development. For example, adiponectin is reported to exert a protective role in CVD. It has been found that oxidized low density lipoprotein (OX-LDL)-treated RAW264.7 cells present remarkable reduction of miR-128-3p expression in a time and dose-dependent manner; while after the transfection of miR-128-3p mimics, it was found that both apoptosis and inflammatory responses were suppressed in RAW264.7 cells (Chen et al. 2018). This suggests that miR-128-3p can repress OX-LDL-induced inflammation and oxidative stress in macrophages, and inhibit the progression of AS.

Methods and materials

Clinical samples
We collected serum samples derived from 48 patients who were diagnosed with carotid atherosclerotic plaque. The inclusion criteria and exclusion criteria of AS patients were as follows: Inclusion criteria: (1) abnormal lipid metabolism; (2) over 40 years old; (3) arteriography revealed a narrowing of the lumen caused by AS; (4) the local intraarterial membrane thickness > 1.5 mm. Exclusion criteria: (1) patients with autoimmune diseases or endocrine and metabolic diseases, including multiple arteritis, rheumatoid arthritis, thyroid dysfunction, adrenocortical dysfunction, diabetes etc.; (2) history of stroke, acute myocardial infarction, etc.; (3) congenital artery stenosis; (4) severe hepatic and renal insufficiency; (5) patients with malignant tumor or who was receiving anti-tumor treatment such as radiotherapy and chemotherapy; (6) pregnant or lactating women.

The inclusion and exclusion criteria of healthy volunteers were as follows: Inclusion criteria: Physical examination, including examination of blood lipids, blood pressure, blood glucose, electrocardiogram, and markers of myocardial injury, etc., revealed no abnormality. Exclusion criteria: (1) diagnosed with AS; (2) history of cardiac arrest, myocardial infarction, or PCI; (3) pregnant or lactating women.

Cell culture and transfection
Human VSMCs were purchased from the Chinese Academy of Sciences (Shanghai, China). The cells were maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Thermo Fisher, HyClone, UT, USA) containing 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, MA, USA) in 5% CO₂ at 37 °C. The medium was changed every 2 days, and the cells were passaged every 4–5 days. The cells in logarithmic phase were harvested for subsequent experiments.
After being trypsinized and resuspended using DMEM, VSMCs were seeded in 6-well plates at a density of 5 × 10^6 cells / well, and when the cell confluency reached 70%, the cells were transfected with pcDNA3.1-FOXO4, pcDNA3.1-MMP9, miR-128-3p mimics, miR-128-3p inhibitors and their corresponding negative controls. All the above plasmids, miRNAs were constructed or synthesized by GenePharma (Shanghai, China). The transfection was performed with Lipofectamine™ 2000 reagent (Invitrogen, Carlsbad, CA, USA). Subsequently, the cells were cultured at 37 °C in 5% CO₂. After 24 h of the transfection, total RNAs was extracted from the cells and the transfection efficiency was detected using quantitative real-time polymerase chain reaction (qRT-PCR).

VSMCs were treated with 0, 25, 50, 75, and 100 mg/L ox-LDL for 24 h or 100 mg/L ox-LDL for 0, 6, 12, 18, and 24 h to establish cell models of AS.

Establishment of mouse model with AS
40 male C57BL/6J mice aged 6–8 weeks were purchased from Center for Animal Experiment of Wuhan University, of which 30 were apolipoprotein E knockout mice (ApoE−/− Mice), and 10 were wild-type (WT) C57BL/6J mice. Of the WT mice, 5 WT mice were fed with normal diet (ND) and 5 were fed with high-fat diet (containing 20% lard oil and 0.25% cholesterol, purchased from Keao Xieli Feed Co., LTD., Beijing, China) for 8 weeks. Of the ApoE−/− mice, 5 were fed with ND and 25 were fed with HFD to establish AS models. All the mice had free access to food and water and were housed with humidity of 50%–60% at 18–22 °C. Manual-controlled room lighting was used to maintain a 12 h light/12 h dark cycle. 20 of these HFD ApoE−/− mice were divided into four groups, 5 mice in each group: mimics NC group, miR-128-3p mimics group, inhibitors NC group, and miR-128-3p inhibitors group. After these four groups of mice were acclimated to the environment for 1 week, miR-128-3p mimics, inhibitors and their corresponding negative controls were dissolved in 0.2 mL of saline at a dose of 40 mg/kg/days and injected into the mice of correspond-

had been approved by the Animal Experiment Ethics Committee of Renmin Hospital of Wuhan University.

qRT-PCR
Total RNAs from human VSMCs, mice carotid artery smooth muscle cells and serum were extracted using TRIzol reagent and serum RNA extraction kit (Invitrogen, Carlsbad, CA, USA). For quantifying FOXO4 and MMP9, 1 μg of the extracted total RNA was reversely transcribed into cDNA with PrimeScript-RT Kit (Takara, Kusatsu, Japan) after the purity was determined. For quantifying miR-128-3p, cDNA was generated via a miRNA reverse transcription kit (Origene, Rockville, MD, USA) according to the manufacturer’s instruction. With cDNA as the template, PCR amplification was performed with SYBR Green Premix Ex Taq II (TaKaRa, Dalian, China) on the Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument (Applied Biosystems, Foster City, CA, USA). The primers used in this study were shown in Table 1. Relative expression was calculated with 2−ΔΔt method.

Western blot
Cells were washed 3 times using pre-cooled PBS. Following that, RIPA lysis buffer (Beyotime Biotechnology, Shanghai, China) containing protease inhibitor was added and mixed thoroughly. The cells were placed on ice for 30 min. After centrifuging at 12,000 g for 10 min at 4 °C, the supernatant was collected and the protein concentration was determined using BCA protein detection kit (Beyotime Biotechnology, Shanghai, China). After that, the protein sample was subjected to electrophoresis and electrotransferred to PVDF membrane (Millipore, Bedford, MA, USA). After being blocked with 5% skim milk for 1 h at room temperature, the primary antibodies (anti-FOXO4 antibody, rabbit anti-human polyclonal antibody, 1:1000, ab63254; or anti-MMP9 antibody, 1:1000, ab30768) were added and incubated overnight at 4 °C, followed by incubation with secondary antibodies (anti-rabbit IgG (H+L) antibody, goat anti-rabbit polyclonal antibody, 1:1000, ab6728; or anti-goat IgG (H+L) antibody, goat anti-rabbit polyclonal antibody, 1:1000, ab6728) for 1 h at room temperature. Finally, the band intensity was quantified by gel imager (Gel Doc ™2000, Bio-Rad, USA) and the protein expression level was expressed as the ratio of the band intensity of target protein to that of β-Actin.

Table 1 Primer sequences used in this PCR

| Name | Primer sequences |
|------|------------------|
| MiR-128-3p | Forward: 5′-GGTCAGTGAACCGGT-3′<br>Reverse: 5′-GTCAGGTTCCGAGGTT-3′ |
| FOXO4 | Forward: 5′-CTTCTGAAGACTGGGAGAATGTG-3′<br>Reverse: 5′-GTCTAGTGTACTGAGCCACG-3′ |
| MMP9 | Forward: 5′-CTGCCGTGAGCACACA-3′<br>Reverse: 5′-AACGGTACGAGATTGT-3′ |
| U6 | Forward: 5′-CTCGGACCCAGCACAA-3′<br>Reverse: 5′-TGCCGATGCGTGCCTTTG-3′ |
| β-Actin | Forward: 5′-GGTCAGTGAACCGGT-3′<br>Reverse: 5′-GTCAGGTTCCGAGGTT-3′ |
rabbit anti-human polyclonal antibody, 1:1000, ab38898) were used to incubate the membranes overnight in a shaker at 4 °C, and the membranes were then rinsed 3 times using TBST the next day. Next, the secondary antibody (goat anti-rabbit IgG, 1:2000, ab205718) was added and the membranes were incubated for 1 h at room temperature in a shaker. After the membranes being washed 3 times using TBST, the protein bands on the membrane were visualized using hypersensitive ECL (Biossci Biotechnology Co., Ltd., Wuhan, China). All antibodies were purchased from Abcam (Shanghai, China). The intensity of each band was analyzed by Image J software.

**CCK-8 assay**

VSMCs in logarithmic phase were harvested, trypsinized and centrifuged. After being resuspended and adjusted to a cell density of $1 \times 10^5$ cells/mL using DMEM, the cells were seeded into 96-well culture plates (100 μL / well) and then cultured at 37 °C in 5% CO2. After 0, 24, 48, 72, and 96 h of culture, 10 μL of CCK-8 solution (Beyotime, Shanghai, China) was added into each wells, respectively. Next, the absorbance of each well at 450 nm wavelength was measured using a microplate reader (ThermoFisher, Waltham, MA, USA). In this assay, each well had three biological replicates and three technical replicates.

**BrdU assay**

VSMCs in logarithmic phase were prepared into single-cell suspensions and seeded into 24-well plates ($1 \times 10^5$ cells/well). 12 h later, BrdU labeled reagents (Beyotime, Shanghai, China) were added into the wells and the incubation was continued for 1 h. The absorbance at 450 nm wavelength was measured using a microplate reader (ThermoFisher, Waltham, MA, USA). The average of the cell proliferation rates in three fields of view under the microscope were randomly selected for cell counting. Cell proliferation rate = BrdU-positive cells / DAPI-positive cells. The average of the cell proliferation rates in three fields was adopted as the final cell proliferation rate.

**Flow cytometry**

AnnexinV-FITC/PI apoptosis detection kit (Yeasen Biotech Co., Ltd., Shanghai, China) was employed to detect the apoptosis of VSMCs. In brief, $1 \times 10^6$ cells in each group were harvested, and resuspended in 100 μL of $1 \times$ binding buffer, followed by the addition of 5 μL of Annexin V-FITC staining solution and 5 μL of PI staining solution to the cells, mixed thoroughly and incubated in dark at room temperature for 15 min. The apoptosis rate was detected by flow cytometry within 1 h.

**Transwell assay**

The cells in each group were trypsinized, and the cells were resuspended using DMEM without serum to adjust the cell density to $1 \times 10^5$ cells/mL, and 200 μL of cell suspension was added to the upper compartment of the Transwell chamber (Corning, Beijing, China), meanwhile 500 μL of DMEM containing 10% FBS was added to the bottom compartment and the cells were cultured at 37 °C, 5% CO2 for 48 h. After the chamber was removed, the cells on the bottom of the membrane were fixed with 4% paraformaldehyde for 15 min, stained with 0.1% crystal violet solution for 15 min, and the remaining crystal violet solution was washed off using PBS, and the cells in the upper chamber were cleaned using a cotton swab. Five fields of view on the membrane under the microscope were used to count the number of cells and the average was calculated to indicate the migration ability of VSMCs.

**Dual-luciferase reporter gene assay**

The genomic DNA was extracted from human VSMCs. Then the FOXO4 3’UTR sequence containing the putative binding site for miR-128-3p was amplified. GeneArt™ site-directed Mutagenesis PLUS System (ThermoFisher, Waltham, MA, USA) was used to mutated the above sequences. After gel electrophoresis of the amplified products, the target sequences were collected, and the above fragments were inserted into the pmirGLO dual-Luciferase miRNA Target expression vector (Promega, Madison, WI, USA). The level of TNF-α, IL-1β and IL-6 in the cell culture supernatant or mice serum were detected using enzyme-linked immunosorbert assay (ELISA) kits (Multisciences, Hangzhou, China) according to the manufacturer’s instructions.

**Determination of inflammatory factors**

The levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and...
high-density lipoprotein cholesterol (HDL-C) in mice serum were detected using corresponding detection kits (Jiancheng Bioengineering Institute, Nanjing, China) according to the manufacturer’s instructions.

Statistical analysis
All data in this study were processed using SPSS 20.0 statistical analysis software (SPSS Inc., Chicago, IL, USA). The measurement data were expressed as “mean ± standard deviation” (x ± s). The comparison between two groups was performed using independent sample t-test. The comparison between multiple groups was analyzed with one-way ANOVA analysis. p < 0.05 signified statistical significance.

Results
miR-128-3p expression was abnormally down-regulated during AS progression
First of all, with bioinformatics analysis, it was found that in Apobtm2Sgy/Ldltm1Her double knockout mice, miR-128-3p expression was significantly reduced in AS lesions in the ascending aorta of mice fed with HFD compared with mice fed with ND after 6 weeks of feeding, based on the public miRNA expression profile dataset GSE89858, but no significant changes were found after 18 and 30 weeks of feeding (Fig. 1a–c). Next, to further investigate the role of miR-128-3p during AS progression, we examined its expression level using qRT-PCR. It was found that miR-128-3p expression was remarkably decreased in the serum of AS patients (Fig. 2a). In ox-LDL-treated VSMCs, the expression level of miR-128-3p was remarkably decreased with the increase of the concentration of ox-LDL and treatment time (Fig. 2b, c). Additionally, compared with wild-type mice fed with ND, the decrease of miR-128-3p expression was observed in the serum and carotid smooth muscle cells of ApoE−/− mice fed with HFD (Fig. 2d, e). The above results indicated that miR-128-3p expression was abnormally reduced in the development of AS.

Effect of miR-128-3p on VSMCs
VSMCs were then treated with different concentrations of ox-LDL for different treatment times in vitro. We observed that, the viability of VSMCs was the highest when treated with 100 mg/L ox-LDL for 24 h (Fig. 3a, b). So this condition was used for the subsequent experiments. To investigate the function of miR-128-3p, we transfected miR-128-3p mimics or inhibitors into VSMCs to up-regulate or inhibit miR-128-3p, respectively (Fig. 3c). The levels of inflammatory factors in supernatants of VSMCs were determined using ELISA. The results showed that miR-128-3p over-expression markedly inhibited the release of TNF-α, IL-6 and IL-1β, while opposite results could be observed in the cells transfected with miR-128-3p inhibitors (Fig. 3d–f). CCK-8 and BrdU assays suggested that miR-128-3p remarkably suppressed the abnormal proliferation of VSMCs, while miR-128-3p inhibitors significantly promoted the viability of VSMCs (Fig. 3g–i). In Transwell assay, it was found that the transfection of miR-128-3p mimics significantly repressed the migration of VSMCs, while the inhibition of miR-128-3p markedly promoted the migration of VSMCs (Fig. 3j). Moreover, through flow cytometry analysis, it was observed that miR-128-3p had a role in promoting apoptosis in VSMCs (Fig. 3k). These results indicated that miR-128-3p suppressed the dysfunction of VSMCs induced by ox-LDL.

miR-128-3p targeted and regulated FOXO4/MMP9
To further explore the downstream mechanism of miR-128-3p, we predicted the downstream target genes of miR-128-3p using TargetScan database and found that
FOXO4 was one of the potential targets of miR-128-3p. Therefore, dual-luciferase reporter gene assay was performed, and it was observed that miR-128-3p mimics significantly reduced the luciferase activity of FOXO4 WT reporter, but there is no significant change presented in FOXO4 MUT group after miR-128-3p mimics were transfected (Fig. 4a, b). We further examined the expressions of FOXO4 and its downstream protein MMP9 using qRT-PCR and Western blot. It was found that the over-expression of miR-128-3p inhibited the expression levels of FOXO4 and MMP9 at both mRNA and protein levels (Fig. 4c–g).

Restoration of FOXO4 or MMP9 reversed the effect of miR-128-3p on VSMCs
To further investigated the mechanism by which miR-128-3p functions, we co-transfected miR-128-3p mimics and pcDNA3.1-FOXO4 or pcDNA3.1-MMP9 into VSMCs. By qRT-PCR and Western blot, we verified that the expression level of FOXO4 or MMP9 was indeed restored after the transfection (Fig. 5a–e). The results of ELISA showed that over-expression of either FOXO4 or MMP9 could attenuate the inhibitory effects of miR-128-3p on ox-LDL-induced inflammatory responses in VSMCs (Fig. 5f–h), and the results of CCK-8 and BrdU assays confirmed that FOXO4 and MMP9 enhanced the proliferation of VSMCs (Fig. 5i–k). Through Transwell assay, it was observed that the inhibitory effect of miR-128-3p on VSMCs migration was also reversed by FOXO4 or MMP9 restoration (Fig. 5l). In addition, compared with that in the miR-128-3p mimics group, the apoptosis rate of VSMCs in miR-128-3p mimics + pcDNA3.1-FOXO4 group or miR-128-3p mimics + pcDNA3.1-MMP9 group was remarkably down-regulated (Fig. 5m).

The biological functions of miR-128-3p in mice
We established animal models with AS by feeding ApoE−/− mice with HFD, followed by the injection of miR-128-3p mimics or inhibitors through the caudal vein to regulate miR-128-3p expressions in vivo. By qRT-PCR, we verified that miR-128-3p expression levels in mice serum and carotid smooth muscle cells were indeed changed after the injection (Fig. 6a, b). Western blot and qRT-PRC indicated that, the expression levels of FOXO4 and MMP9 at both mRNA and protein levels in mice carotid smooth muscle cells were also disturbed (Fig. 6c–g). The results of ELISA suggested that the injection of
Fig. 3  Effect of miR-128-3p on VSMCs.  

a CCK-8 assay was used to determine the viability of VSMCs treated with different concentrations of ox-LDL for 24 h.  
b CCK-8 assay was used to determine the viability of VSMCs treated with 100 mg/L ox-LDL for different stimulating times.  
c The transfection efficiency of miR-128-3p mimics and inhibitors was examined using qRT-PCR. The levels of inflammatory cytokines TNF-α (d), IL-1β (e) and IL-6 (f) in the supernatants of VSMCs were measured using ELISA.  
g, h VSMCs proliferation was measured using CCK-8 assay after the transfection.  
i VSMCs proliferation was measured using BrdU assay after the transfection.  
j VSMCs migration was examined using Transwell assay after the transfection.  
k VSMCs apoptosis was detected using flow cytometry after the transfection. *, **, *** represent p < 0.05, p < 0.01, p < 0.001, respectively.

Fig. 4  Effect of miR-128-3p on FOXO4 and MMP9.  

a Predicted binding site between miR-128-3p and the 3′UTR of FOXO4.  
b The binding relationship between miR-128-3p and FOXO4 3′UTR was verified by dual luciferase reporter gene assay.  
c Western blot was used to detect FOXO4 and MMP9 expressions after transfection.  
d–g The quantification of FOXO4 and MMP9 at the mRNA and protein levels in VSMCs after miR-128-3p was overexpressed or inhibited. *, **, *** represent p < 0.05, p < 0.01, p < 0.001, respectively.
miR-128-3p mimics reduced the inflammatory responses in mice (Fig. 6h–j). In addition, it was also found that TG, TC, and LDL-C levels in the serum of the mice in miR-128-3p mimics group were markedly reduced, while HDL-C level was significantly increased (Fig. 6k–n). Collectively, it was confirmed that miR-128-3p suppressed VSMCs dysfunction and regulated blood lipid levels through specific regulation of FOXO4/MMP9 axis.

Discussion
In the present study, it was demonstrated that miR-128-3p was significantly down-regulated in the serum of AS patients, the serum of AS mice, the carotid artery smooth muscle cells of AS mice, and ox-LDL-treated VSMCs, and miR-128-3p could not only attenuate the inflammatory responses of VSMCs and inhibit their abnormal proliferation and migration, but also reduce the lipid levels in the serum of mice. In glioma, miR-128-3p expression is remarkably reduced, and it inhibits the proliferation and migration of glioma cells by specific inhibition of GREM1 (Fu et al. (2018)). In esophageal squamous cell carcinoma, miR-128-3p, which is lowly expressed, inhibits the migration of cancer cells through inhibiting ZEB1 (Zhao et al. 2018). Reportedly, selenium markedly increases the expression of miR-128-3p and suppresses the MAPK signaling pathway, which in turn reduces the levels of proinflammatory factors including TNF-α and IL-1 in LPS-induced chicken myocardial inflammation (Liu et al. 2020a). These studies imply that miR-128-3p is an inhibitor for proliferation, migration
and inflammation, which is consistent with the demonstrations in the present work. Notably, a recent research reports that miR-128-3p is significantly down-modulated in VSMCs treated with PDGF-BB or hypoxia, and the aortic samples of ApoE−/− mice fed with Western diet; overexpression of miR-128-3p decreases VSMCs proliferation, migration and helps VSMCs maintain a contractile phenotype (Farina et al. 2020). The results are consistent with the present study.

MiRNAs often exert their function by inhibiting the post-transcriptional translation of their downstream target genes. In this work, it was also confirmed that miR-128-3p could suppress FOXO4 expression, and the functions of miR-128-3p in regulating the phenotypes of VSMCs were mediated by FOXO4. In cancer research, FOXO4 is often considered to have a role in impeding cell proliferation (Liu et al. 2011; Chen et al. 2013). However, in the present study, it was observed that the FOXO4 had a role in enhancing the proliferation and migration of VSMCs, which was different from its role in cancer cells. FOXO4 expression is significantly higher in damaged arteries, and lncRNA XR007793 facilitates the proliferation and migration of VSMCs by indirectly up-regulating FOXO4 (Wu et al. 2018). Under the stimulation of ox-LDL, lncRNA LINC00341 expression is increased in VSMCs, which enhances the proliferation and migration...
of VSMCs by promoting the expression of FOXO4 (Liu et al. 2019a). The above demonstrations are consistent with our work, and collectively, we suppose that inhibiting FOXO4 will probably block the progression of AS via repressing the dysfunction of VSMCs. Importantly, miR-128-3p may not only regulate FOXO4 expression through binding its 3′UTR. MiR-128-3p is reported to regulate various pathways / genes, which can probably regulate FOXO4 expression, including Erk signaling, SIRT1, PI3K/AKT pathway and so on (Liu et al. 2020b, 2019b; Wang et al. 2014; Zhao et al. 2019b; Kobayashi et al. 2005; Huo et al. 2019; Chen and Li 2020; Gong et al. 2019; Chang et al. 2013) (Fig. 7). In VSMCs, whether miR-128-3p indirectly modulates FOXO4 expression through these mechanisms needs more investigations in the future.

MMP9 is an important regulator in inflammatory response. Leukocytes recruited by the inflammatory responses produce a variety of cytokines and chemokines that facilitate the release of MMP9, which also has a role in promoting the activation of inflammatory factors such as IL-1β, forming a positive feedback (Li et al. 2007; Deleon-Pennell et al. 2015). MMP9 is often increased when AS occurs, and the level of MMP9/NGAL complex is strongly related to the vulnerability of AS plaques (Eilenberg et al. 2017; Wu et al. 2019). It is reported that the expression of MMP9 is positively regulated by FOXO4 (Li et al. 2007), which is consistent with our findings. We suppose that, at least partly, miR-128-3p and FOXO4 exert their biological functions through regulating MMP9 in AS development.

Hyperlipidemia and dysregulation of lipoproteins are important factors in AS pathogenesis. In hyperlipidemia, circulating platelets are activated, accompanied by increased platelet aggregation, platelet-leukocyte aggregate formation, and platelet-induced superoxide anion production; furthermore, ox-LDL induces monocytes’ adhesion to endothelium, migration and proliferation of smooth muscle cells. These biological events contributes to AS progression (Siegel-Axel et al. 2008; Bühler et al. 1991). Interestingly, in the present work, we found that injection of miR-128-3p mimics significantly reduced LDL-C, TG, TC but elevated HDL-C in the plasma of mice, which suggested that miR-128-3p may also repress AS progression via regulating lipid metabolism, but the detailed mechanism needs further clarification.

Conclusion

In conclusion, with in vitro and in vivo models, this work indicates that miR-128-3p/FOXO4/MMP9 axis regulates AS progression via modulating the inflammatory response, proliferation and migration of VSMCs. Our research further elucidates the molecular mechanism of AS development, and provides novel insights into prevention and treatment of CVD.

Acknowledgements

We thank Hubei Yican Health Industry Co., Ltd for its linguistic assistance during the preparation of this manuscript.

Authors’ contributions

CQ and BY conceived and designed the experiments. CQ, XL and YG collected clinical samples and conducted experiments. YHF, XHC and JNZ analyzed data. CQ, XL and YG wrote the manuscript. All authors read and approved the final manuscript.

Funding

Not applicable.

Availability of supporting data

The data used to support the findings of this study are available from the corresponding author upon request.

Ethics approval and consent to participate

This study was approved by the Ethics Committees of Renmin Hospital of Wuhan University. Written informed consents were acquired from each participating patient. All protocols were conducted in accordance with the principles of the Declaration of Helsinki. The protocols of the animal experiments had been approved by the Animal Experiment Ethics Committee of Renmin Hospital of Wuhan University. The animal experiments were conducted in compliance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and Animal Welfare Act.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 21 May 2020 Accepte: 12 November 2020 Published online: 25 November 2020

References

Balzan S, Lubrano V. LOX-1 receptor: a potential link in atherosclerosis and cancer. Life Sci. 2018;198:79–86.

Bejarano J, Navarro-Marquez M, Morales-Zavala F, Morales JO, Garcia-Carvajal I, Araya-Fuentes E, et al. Nanoparticles for diagnosis and therapy of
atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Thera. 2018;8:4710–32.

Bühler FR, Tkachuk VA, Hahn AW, Resnik TJ. Low- and high-density lipoproteins as hormonal regulators of platelet, vascular endothelial and smooth muscle cell interactions: relevance to hypertension. J Hypertens Suppl. 1991;9:S28–6.

Byon CH, Han T, Wu J, Hui ST. Tenip ablation reduces vascular smooth muscle cell inflammation and ameliorates atherosclerosis in apolipoprotein E knockout mice. Atherosclerosis. 2015;241:313–21.

Chang B, Sang L, Wang Y, Tong J, Wang B. The role of FoxO4 in the relationship between alcohol-induced intestinal barrier dysfunction and liver injury. Int J Mol Med. 2013;31:569–76.

Chen S, Li B. MiR-128-3p post-transcriptionally inhibits WSP1 to suppress apoptosis and inflammation in human articular chondrocytes via the PI3K/AKT/FOXO signaling pathway. Cell Transplant. 2020;29:963689720939131.

Chen L, Tang Y, Wang J, Yan Z, Xu R. miR-421 induces cell proliferation and apoptosis resistance in human nasopharyngeal carcinoma via downregulation of FOXD4. Biochim Biophys Res Commun. 2013;435:745–50.

Chen DD, Hui LL, Zhang XC, Chang Q. NEAT1 contributes to ox-LDL-induced inflammation and oxidative stress in macrophages through inhibiting miR-128. J Cell Biochem. 2018. https://doi.org/10.1002/jcb.27541.

Deleon-Pennell KY, Altara R, Yabluchanskiy A, Modesti A, Lindsey ML. The circadian relationship between matrix metalloproteinase-9 and inflammation following myocardial infarction. IUBMB Life. 2015;67:611–8.

Di Gregorio K, Mohammad Anuar NN, Bianco R, White SJ, Nevbvy AC, George SJ, et al. MicroRNA-181b controls atherosclerosis and aneurysms through regulation of TIMP-3 and Elastin. Circ Res. 2017;120:49–55.

Eilenberg W, Stojkovic S, Kader A, Kozakowski N, Domenech CM, Burghuber C, et al. NGAL and MMP-9/NGAL as biomarkers of plaque vulnerability and targets of statins in patients with carotid atherosclerosis. Clin Chem Lab Med. 2017;56:147–56.

Farina FM, Hall IF, Senio S, Zani S, Climent M, Salvarani N, et al. miR-128-3p is a novel regulator of vascular smooth muscle cell phenotypic switch and vascular diseases. Circ Res. 2020;126:120–35.

Fu C, Li D, Zhang X, Liu N, Chi G, Jin X. LncRNA PVT1 facilitates tumorigenesis and progression of glioma via regulation of MiR-128-3p/GREM1 Axis and BMP signaling pathway. Neurotherapeutics. 2018;15:1139–57.

Gholipour S, Sewell RDE, Lorigooini Z, Rafieian-Kopaei M. Medicinal plants and atherosclerosis: a review on molecular aspects. Curr Pharm Des. 2018;24:3123–31.

Gong C, Ai J, Fan Y, Gao J, Liu W, Feng Q, et al. NCPAP promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling. Oncol Targets Ther. 2019;12:e5837–52.

Huo L, Wang B, Zheng M, Zhang Y, Xu J, Yang G, et al. miR-128-3p inhibits glioma cell proliferation and differentiation by targeting NPTX1 through IRS-1/PI3K/AKT signaling pathway. Exp Ther Med. 2019;17:2921–30.

Liang J, Castillon DH, DePinho RA, Olson EN, Liu ZP FoxO4 regulates tumor necrosis factor alpha-directed smooth muscle cell migration by activating matrix metalloproteinase 9 gene transcription. Mol Cell Biol. 2007;27:2676–86.

Lim S, Park S. Role of vascular smooth muscle cell in the inflammation of atherosclerosis. BMJ Rep. 2014;4:71–7.

Liu X, Zhang Z, Sun L, Chai N, Tang S, Jin J, et al. MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and POCD4. Carcinogenesis. 2011;32:1798–805.

Liu X, Ma BD, Liu S, Liu J, Ma BX. Long noncoding RNA LINC00341 promotes the vascular smooth muscle cells proliferation and migration via miR-214/FOXO4 feedback loop. Am J Transl Res. 2019;11:1835–42.

Liu H, Wang L, Weng X, Chen H, Du Y, Diao C, et al. Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FOXO4-mediated oxidative stress. Redox Biol. 2019;24:101195.

Liu J, Wang S, Zhang Q, Li X, Xu S. Selenomethionine alleviates LPS-induced chicken myocardial inflammation by regulating the miR-128-3p-p38 MAPK axis and oxidative stress. Metallomics. 2020;12:54–64.

Liu X, Dong C, Ma S, Wang Y, Lin T, Li Y, et al. Nanocomplexes loaded with miR-128-3p for enhancing chemotherapy effect of colorectal cancer through dual-targeting silence the activity of PI3K/AKT and MDR/ERK pathway. Drug Deliv. 2020;27:323–33.

Moss JW, Jamji DP. Nutraceutical therapies for atherosclerosis. Nat Rev Cardiol. 2016;13:513–32.

Orekhon AV, Ivanova EA. Cellular models of atherosclerosis and their implication for testing natural substances with anti-atherosclerotic potential. Phytomedicine. 2016;23:1190–7.

Paone S, Baxter AA, Hulett MD, Poon IKH. Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis. Cell Mol Life Sci. 2019;76:1093–106.

Siegel-Axel D, Daub K, Seifer P, Lindemann S, Gavazw M. Platelet lipidprotein interplay: trigger of foam cell formation and driver of atherosclerosis. Cardiovasc Res. 2008;78:88–93.

Wang J, Yuan L, Xiao H, Wang C, Xiao C, Wang Y, et al. A novel mechanism for momordin Ic-induced HepG2 apoptosis: involvement of PI3K- and MAPK-dependent PPARα activation. Food Funct. 2014;5:859–68.

Wang W, Zhou PH, Hu W. Overexpression of FOXO4 induces apoptosis of clear-cell renal carcinoma cells through downregulation of Bim. Mol Med Rep. 2016;13:2229–34.

Wu YY, Zhang SH, Cui J, Liu FT. Long noncoding RNA XRX007793 regulates proliferation and migration of vascular smooth muscle cell via suppressing miR-23b. Med Sci Monit. 2018;24:5895–903.

Wu X, Chen L, Zieb F, Li C, Jiang P, Chen A, et al. Clock-Bmal1 mediates MMP9 induction in acrolein-promoted atherosclerosis associated with gut microbiota regulation. Environ Pollut. 2019;252:1455–63.

Zhang L, Yuan M, Zhang L, Wu B, Sun X. Adiponectin alleviates NLRP3-mediated inflammatory stress in macrophages through inhibiting FoxO4 in atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Thera. 2018;8:4710–32.

Zhang L, Yuan M, Zhang L, Wu B, Sun X. Adiponectin alleviates NLRP3-mediated inflammatory stress in macrophages through inhibiting FoxO4 in atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Thera. 2018;8:4710–32.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.